In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average Lilly has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity INDIANAPOLIS, Dec. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agon

INDIANAPOLIS, Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing d

As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a year These data were published simultaneously in Annals of Oncology and will be presented today at the 2025 San Antonio Breast Cancer Symposium INDIANAPOLIS, Dec. 12, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients w

In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial  Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026 INDIANAPOLIS, Dec. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical

Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines. Importantly, the site will be amo

INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)  and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the st

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition, and were featured as part of the meeting's press program   INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve p

INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees. "On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks, Lilly chair and CEO. "Carolyn is a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer. As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable. We're fortunate to have her back a

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or death in the ITT population, and the treatment-naïve subgroup, which had the longest follow up, showed a 76% reduction These data will be simultaneously published in the Journal of Clinical Oncology and presented at the 2025 American Society of Hematology Annual Meeting and Exposition, as well as featured

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

3 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

8-K - ELI LILLY & Co (0000059478) (Filer)

144 - ELI LILLY & Co (0000059478) (Subject)

10-Q - ELI LILLY & Co (0000059478) (Filer)

8-K - ELI LILLY & Co (0000059478) (Filer)

8-K - ELI LILLY & Co (0000059478) (Filer)

FWP - ELI LILLY & Co (0000059478) (Subject)

10-Q - ELI LILLY & Co (0000059478) (Filer)

8-K - ELI LILLY & Co (0000059478) (Filer)

144 - ELI LILLY & Co (0000059478) (Subject)

11-K - ELI LILLY & Co (0000059478) (Filer)

Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

BofA Securities reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,268.00 from $1,286.00 previously

Scotiabank initiated coverage of Eli Lilly with a rating of Sector Outperform and set a new price target of $1,165.00

Leerink Partners upgraded Eli Lilly from Market Perform to Outperform and set a new price target of $1,104.00

BMO Capital Markets reiterated coverage of Eli Lilly with a rating of Outperform and set a new price target of $930.00 from $840.00 previously

Erste Group upgraded Eli Lilly from Hold to Buy

Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00

HSBC Securities upgraded Eli Lilly from Reduce to Hold and set a new price target of $700.00

Daiwa Securities downgraded Eli Lilly from Outperform to Neutral and set a new price target of $700.00

For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

For Immediate Release: September 23, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “FDA Issues New Guidance to Help Facilitate Availability of Naloxone to Prevent Opioid Overdoses and Reduce Death,” by Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Center f

For Immediate Release: June 13, 2022 Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific locati

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

4 - ELI LILLY & Co (0000059478) (Issuer)

INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024. Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan and dean of the Medical School, and he plans to retire on June 30, 2025. Following retirement from these leadership roles, Dr. Runge will remain on the Medical School faculty as a prof

INDIANAPOLIS, June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year. "As we expand global capacity to meet demand and support pipeline growth, we remain committed to ensuring our medicines are produced to the highest quality standards," said David A. Ricks, Lilly's chair and CEO. "With more than 25 years of experience and a proven

INDIANAPOLIS, May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer. "Throughout his distinguished career, Alonzo has been a steadfast advocate for our company, providing strategic guidance to our global product development teams and major geographies worldwide," said David A. Ricks, Lilly's

INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly. "Through his deep financial knowledge and understanding of the business, industry and stakeholders, Phil has played a key leadership role in the company and is well recognized for his commitment to Lilly's purpose and the patients we serve. Additionally, he is known for his pass

INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. Regulatory progre

INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new d

INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heal

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi

INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into hea

INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

SC 13G/A - ELI LILLY & Co (0000059478) (Subject)